Safe Drinking Water Act Overview Environmental Law 2

  • Slides: 13
Download presentation
Safe Drinking Water Act Overview Environmental Law 2 Spring 2005

Safe Drinking Water Act Overview Environmental Law 2 Spring 2005

Mapping the Act • Major program areas-drinking water standard-setting • Regulatory instruments--command -and-control with

Mapping the Act • Major program areas-drinking water standard-setting • Regulatory instruments--command -and-control with disclosure

Key Distinctions 1: • Large vs. small systems • Cost-benefit vs. other ways of

Key Distinctions 1: • Large vs. small systems • Cost-benefit vs. other ways of dealing with cost • MCLGs vs MCLs

Underlying cost problems • Cost increases supralinear, benefits gains sublinear • Economies of scale

Underlying cost problems • Cost increases supralinear, benefits gains sublinear • Economies of scale (e. g. , GAC) • Time spread--costs are now, benefits are (much) later • Cost increases are lumpy (e. g. , GAC filtration) • SDWA drives Superfund cleanups (MCLGs)

Standard-Setting • Risk Assessment-MCLGs • NOAEL + adequate margin of safety • “What would

Standard-Setting • Risk Assessment-MCLGs • NOAEL + adequate margin of safety • “What would it be if we didn’t have to worry about cost? ” • Risk Management--MCLs • Feasibility Analysis--“Best available technology taking cost into consideration” • Originally gave variances and exceptions for small systems

The Escalation of CBA Trihalomethanes (late ’ 70 s) • Student publication: EPA should

The Escalation of CBA Trihalomethanes (late ’ 70 s) • Student publication: EPA should mandate high-cost treatment • White House CWPS— CBA indicates small system deregulation • EPA— CBA marginal benefit analysis justifies the rule w/ small system exceptions

EPA Policy: Zero MCLG for Known or Probable Carcinogens • Group A--Known Human Carcinogen

EPA Policy: Zero MCLG for Known or Probable Carcinogens • Group A--Known Human Carcinogen • Group B 1 --Probable human carcinogen, limited human epi data • Group B 2 --Probable human carcinogen; inadequate human, adequate animal data • Group C--Possible carcinogen--no human and limited animal data • Group D--Unclassifiable • Group E--No evidence of carcinogenicity, tests are adequate

Is cancer really a no-threshold toxin? Bruce Ames says “Maybe not” International Fabricare Institute,

Is cancer really a no-threshold toxin? Bruce Ames says “Maybe not” International Fabricare Institute, 972 F. 2 d 384 (1992)

EPA Policy: GAC Filtration Is a “Feasible” Technology for Synthetic Organic Chemicals • Pentachlorphenol

EPA Policy: GAC Filtration Is a “Feasible” Technology for Synthetic Organic Chemicals • Pentachlorphenol example: • In a system serving 62, 000 people, save 1 life in 1, 650 years at a cost of $860 m • In a system serving 250 people, save one life in 500, 000 years, at a cost of $5. 4 billion

Political imperatives • Environmental community opposes CBA, exemptions for small systems • Small systems

Political imperatives • Environmental community opposes CBA, exemptions for small systems • Small systems could not afford GAC filtration, even if the federal government gave them the plants • Proliferating MCLs make testing and reporting costly, difficult • Unfunded mandates and small business impacts make regulation difficult • Health scares focus public attention on drinking water

A Great Lakes problem: if we limit diversions, we may increase health risks

A Great Lakes problem: if we limit diversions, we may increase health risks

A general problem: How do you do a cost-benefit analysis for something that isn’t

A general problem: How do you do a cost-benefit analysis for something that isn’t dose-dependent (the hormone mimics)

Another general problem: How do you deal with especially sensitive populations? • EPA must

Another general problem: How do you deal with especially sensitive populations? • EPA must consider: “The effects of the contaminant on the general population and on groups within the general populations such as infants, children, pregnant women, the elderly, individuals with a history of serious illness, or other subpopulations that are identified as likely to be at greater risk of adverse health effects due to exposure to contaminants in drinking water than the general population. ”